BRIMONIDINE TARTRATE 0.25% / POTASSIUM AZELOYL DIGLYCINATE 8%- brimonidine tartrate 0.25% / potassium azeloyl diglycinate 8% gel
Sincerus Florida, LLC

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

----------

BRIMONIDINE TARTRATE 0.25% / POTASSIUM AZELOYL DIGLYCINATE 8%

Directions for use

Sincerus Florida, LLC. Advese reactions

Active, inactive

NDC 72934- 1027-2 BRIMONIDINE TARTRATE USP 0.25% . Gel 30gm

BRIMONIDINE TARTRATE 0.25% / POTASSIUM AZELOYL DIGLYCINATE 8%
brimonidine tartrate 0.25% / potassium azeloyl diglycinate 8% gel

Product Information
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:72934-1027
Route of Administration	TOPICAL

Ingredient Name	Basis of Strength	Strength
Active Ingredient/Active Moiety
BRIMONIDINE TARTRATE (UNII: 4S9CL2DY2H) (BRIMONIDINE - UNII:E6GNX3HHTE)	BRIMONIDINE TARTRATE	0.25 g in 100 g

Product Characteristics
Color	white	Score
Shape		Size
Flavor		Imprint Code
Contains

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
Packaging
1	NDC:72934-1027-2	30 g in 1 BOTTLE, PUMP; Type 0: Not a Combination Product	05/16/2019

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
Marketing Information
unapproved drug other		05/16/2019

Labeler - Sincerus Florida, LLC (080105003)

Name	Address	ID/FEI	Business Operations
Establishment
Sincerus Florida, LLC		080105003	manufacture(72934-1027)